Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharma (ALNY) Tops Q4 EPS by 24c
February 6, 2020 8:08 AM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.98), $0.24 better than the analyst estimate of ($2.22). Revenue for the quarter came in at $71.68 million versus the consensus estimate of $71.92 million.
Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, RespectivelyAs of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with PatisiranObserved Strong Initial Demand for GIVLAARI (givosiran) in the U.S., with 13 Start Forms Received in First Six Weeks after FDA ApprovalReported Third Positive 2019 Phase 3 Result with... More